Coya Therapeutics, Inc.

Coya Therapeutics, Inc. (COYA) priced its initial public offering on Dec 30, 2022 at $5.00 per share, raising $15.2M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $48.4M. Chardan was lead-left underwriter, joined by Newbridge and Joseph Gunnar.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company developing proprietary therapies that enhance the function of regulatory T cells (Tregs), which suppress inflammatory responses. It has no products approved for commercial sale and relies on licensed autologous Treg technology.

Status

IPO

Ticker

COYA

Exchange

Nasdaq Capital Market

Priced

Dec 30, 2022

IPO price

$5.00

Raised

$15.2M

Market cap at IPO price

$48.4M

First filed

Nov 18, 2022

Underwriters

Chardan, Newbridge and Joseph Gunnar

Sector

Biotech & pharma

Country / state

TX

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.